Skip to main content
Laekna, Inc. logo

Laekna, Inc. — Investor Relations & Filings

Ticker · 2105 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 130 across all filing types
Latest filing 2025-07-31 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2105

About Laekna, Inc.

http://www.laekna.com

Laekna, Inc. is a science-driven, clinical-stage biotechnology company founded in 2016. The company specializes in the discovery, development, and commercialization of innovative therapies, particularly focusing on immunology treatments. Laekna's core mission is to bring novel therapeutics to patients suffering from cancer (oncology), metabolic diseases, and liver fibrosis, addressing significant unmet medical needs across these therapeutic areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE103 WAS OBTAINED FROM THE U.S. FOOD AND DRUG ADMINISTRATION
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on the HKEX concerning an FDA investigational new drug approval. It does not report financial results, AGM materials, board changes, dividends, or other specific events, nor does it attach a full report. It is a general business update regulatory announcement, which falls into the fallback ‘Regulatory Filings’ category (RNS).
2025-07-31 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement (1,266 characters) notifying shareholders of the date of a Board meeting to consider and approve the Company’s interim results and their publication. It does not contain the actual financial results or updates but simply advises on the timing of the report’s approval and forthcoming release. Under the “menu vs meal” rule, such a notice falls under Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports.
2025-07-29 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
Regulatory Filings Classification · 1% confidence The document is a Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules” filed with the HKEX. It is a routine regulatory compliance filing detailing movements in share capital, share options, warrants, convertibles, and other share arrangements for the month ended 30 June 2025. It is not an earnings release, annual or interim report, proxy statement, board change notice, or other specifically enumerated category. Therefore it falls under the fallback category for general regulatory filings (RNS).
2025-07-04 English
VOLUNTARY ANNOUNCEMENT SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE103 TO THE U.S. FOOD AND DRUG ADMINISTRATION
Regulatory Filings Classification · 1% confidence The document is a short voluntary announcement regarding the Company’s submission of an IND application to the U.S. FDA. It is not an earnings release, not an annual or interim report, nor a financing or M&A transaction, and contains no director changes, share transactions, or dividend notices. It is a general corporate announcement for regulatory or market disclosure. As it does not fit any of the specific categories (ER, IR, CAP, TAR, etc.), it falls under the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2025-06-30 English
VOLUNTARY ANNOUNCEMENT PRESENTATIONS OF CLINICAL AND PRECLINICAL STUDIES RESULTS OF LAE02, LAE03 AND LAE123 AT 2025 ADA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement of clinical/preclinical study presentations at a scientific conference (the ADA) by Laekna, Inc. It does not contain financial results, dividend notices, share transactions, or management/board changes, nor is it an investor slide deck or formal annual/interim report. It does not fit any of the highly specific categories, so it defaults to the general regulatory announcement/fallback category: Regulatory Filings (RNS).
2025-06-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
Regulatory Filings Classification · 1% confidence The document is a standardized HKEX form FF301 (“Monthly Return for Equity Issuer...on Movements in Securities”) filed under the Exchange Listing Rules, detailing monthly movements in authorised share capital, issued shares, share options and confirmations under Main Board Rule 13.25C/GEM Rule 17.27C. It is not an earnings announcement, AGM material, management discussion, nor a standalone capital-raising prospectus. It is a routine regulatory submission summarising share movements (even though no movement occurred). This falls under general ‘Regulatory Filings’ rather than a specific category like SHA, CAP, or POS.
2025-06-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.